Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06880549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 9 words
  2. Enrollment reopened
    • Study sites: 3 to 4
    v6
  3. Primary and study completion moved earlier from Jan 10, 2029 to Aug 3, 2027v5 Show 4 more changesShow less
    • Enrollment reduced: 57 → 42 participants
    • Interventions: Nivolumab/Relatlimab (Biological), mRNA-4106 (Biological) to Pembrolizumab (Biological), mRNA-4106 (Biological), mRNA-4200 (Biological)
    • Eligibility criteria expanded, about 70 words
    • Study title expanded, about 1 word
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v4
  5. Site details revised at 2 of 3 sitesv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 14, 2025 to Mar 25, 2025
    • Site details revised at 3 of 3 sites
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Trial Details
NCT Number NCT06880549
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Advanced Solid Tumors
Related terms Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov